Intravenous Infusions is trading 8.62% down at GHS 0.53 as profit-taking continues after a speculative rally.
- Selling began after the share price reached GHS 0.86 on July 30.
- First-half revenue declined 39% despite improved margins and a return to profitability.
- The decline appears primarily technical rather than driven by a new August 11 announcement.